An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

Inclusion Criteria:

• For women of childbearing potential, agreement to remain abstinent (refrain fromheterosexual intercourse) or use contraception, during the study for at least 28days after the last fluorescein injection for the fluorescein angiography (FA)administration

• Study eye: High-risk intermediate AMD

Exclusion Criteria:

• Macular disease in either eye with subretinal deposits not typical of AMD

• Pigmentary abnormalities of the retina in either eye not typical of AMD

• Atrophy in either eye due to causes other than AMD

• Study eye: Any concurrent or history of ocular or intraocular condition

• Study eye: Intraocular surgery, including cataract surgery, within 3 months prior toDay 1

• Study eye: Retinal tears or peripheral retinal breaks within 3 months prior to Day 1

• Study eye: Concurrent or history of retinal laser photocoagulation or anti-vascularendothelial growth factor (anti-VEGF) treatment for exudative MNV, diabetic macularedema, retinal vein occlusion, or proliferative diabetic retinopathy

• Study eye: Presence of choroidal nevus with overlying drusen in the circle with aradius 3600 micrometer centered on the fovea

• Study eye: Previous participation in interventional clinical trials for GA or earlystages of AMD, except for vitamins and minerals, regardless of the route ofadministration within the last 6 months, except for sham-arm participants

• Study eye: History of glaucoma surgery, corneal transplant, retinal pigmentepithelium tear, retinal tear that involves the macula, retinal detachment

• Either eye: Uncontrolled progressive glaucoma

• Either eye: Moderate or severe non-proliferative diabetic retinopathy orproliferative diabetic retinopathy

• Either eye: History of recurrent infectious or inflammatory ocular disease

• Any concurrent or history of taking medications that can induce retinal toxicity